Mirati

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Monday, December 5, 2022
Data, Therapy, Trae tha Truth, Oncology, Judgement, ORR, European Society for Medical Oncology, Large-cell lung carcinoma, Central nervous system, Doctor of Philosophy, Life, TAM, MTA, AST, Patient, DCR, Cancer, Dana–Farber Cancer Institute, Science, NSCLC, Lung cancer, Research, ALT, PD-1, Incidence, Safety, ESMO, Colorectal cancer, LFT, Multimedia, CET, SOS1, Congress, SAN, PRMT5, Pancreatic cancer, Communications satellite, Pharmaceutical industry, Medical imaging, MD, Mirati

75 patients were enrolled and evaluable for safety with a median follow-up of 3.5 months (duration of treatment: 2 months).

Key Points: 
  • 75 patients were enrolled and evaluable for safety with a median follow-up of 3.5 months (duration of treatment: 2 months).
  • Treatment-related adverse events (TRAEs) were Grade 1-2 (39%), Grade 3 (40%) and Grade 4 (4%); there were no Grade 5 TRAEs observed.
  • TRAEs led to discontinuation of both adagrasib and pembrolizumab in 2 patients and only pembrolizumab in 2 patients; there were no patients who discontinued only adagrasib due to a TRAE.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

Retrieved on: 
Friday, December 2, 2022
KIT, NSCLC, Receptor tyrosine kinase, VEGFR2, SAPPHIRE, Judgement, TAM, Mer, Large-cell lung carcinoma, Therapy, Cancer, Research, Life, PRMT5, Patient, TYRO3, Science, Lung cancer, SAN, Nivolumab, Pharmaceutical industry, Mirati

SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that based on the results of an interim analysis on overall survival, the registrational Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the study's final analysis. The final analysis is expected to be reached in mid-2023.

Key Points: 
  • "We remain committed to developing our portfolio of oncology candidates and advancing our lung cancer strategy to positively impact the lives of patients with cancer.
  • Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12Dinhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.
  • For more information about Mirati Therapeutics, Inc., visit us at Mirati.com or follow us on Twitter and LinkedIn .
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO

Retrieved on: 
Monday, November 28, 2022
Judgement, SAN, Science, NSCLC, Congress, MTA, Therapy, Life, PRMT5, Patient, SOS1, Oncology, Pembrolizumab, ESMO, Lung cancer, CET, Cancer, TAM, European Society for Medical Oncology, Pharmaceutical industry, Mirati

Mirati Therapeutics will host a Virtual Investor Event following the session on Wednesday, December 7, 2022 at 5:00 p.m. CET / 11:00 a.m.

Key Points: 
  • Mirati Therapeutics will host a Virtual Investor Event following the session on Wednesday, December 7, 2022 at 5:00 p.m. CET / 11:00 a.m.
  • A replay of the presentation will be available approximately 2 hours after the event has ended at the same website.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").
  • Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati.

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

Retrieved on: 
Monday, November 7, 2022
Partnership, Research, Colorectal cancer, Exercise, PD-1, Revolution, Conference, Security (finance), Merck & Co., Forward-looking statement, Pancreatic cancer, Mouse Models of Human Cancer database, Amgen, Attention deficit hyperactivity disorder predominantly inattentive, Helmy Eltoukhy, Drug discovery, U.S. Securities and Exchange Commission, Ras GTPase, CRC, Neoplasm, GAAP, Patient, COVID-19, Mutation, Mirati, Nasdaq, Merck, Webcast, Cancer, SHP2, Terminology, Growth, Phosphorylation, GLOBE, Private Securities Litigation Reform Act, Large-cell lung carcinoma, Lung cancer, D, Pembrolizumab, Merck Sharp & Dohme Federal Credit Union, Pharmaceutical industry, Air cargo, NSCLC, Sanofi

REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2022, and provided an update on corporate progress.

Key Points: 
  • In August 2022, Amgen reported preliminary results from this trial at the IASLC 2022 World Conference on Lung Cancer.
  • During the quarter ended September 30, 2022, the company recorded a non-cash GAAP accounting adjustment that reduced collaboration revenue by $4.6 million.
  • Revolution Medicines will host a webcast this afternoon, November 7, 2022, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
  • Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, November 8, 2022
Food, Pembrolizumab, IND, NASDAQ, NDA, Oncology, Lung cancer, Judgement, U.S. Securities and Exchange Commission, Meekness, Growth, FDA, Patient, SEC, TAM, Company, Fast Track, CRC, SAN, European Society for Medical Oncology, Cancer, NSCLC, ESMO, Trial of the century, Life, Program, MTAP, Prescription Drug User Fee Act, CMO, Cetuximab, Retirement, PDUFA, SOS1, Neoplasm, Investment, Nivolumab, Science, Leadership, Food and Drug Administration Amendments Act of 2007, Investigational New Drug, Incyte, SAPPHIRE, Research, PRMT5, Therapy, MTA, Congress, Pharmaceutical industry, Management, Medical device, Aquaculture, Facebook, BeiGene, Mirati

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates.

Key Points: 
  • SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates.
  • We continue to advance our pipeline and capabilities, further enabling Mirati to transform the lives of people living with cancer."
  • ET / 1:30 p.m. PT during which company executives will review financial information for the third quarter of 2022 and provide corporate updates.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

Retrieved on: 
Tuesday, November 8, 2022
Oregon Health and Science University Center for Women's Health, NASDAQ, Lung cancer, Judgement, U.S. Securities and Exchange Commission, Industry, Patient, SEC, TAM, Company, Ponce Health Sciences University, SAN, Board, Cancer, Director, Schering-Plough, Internal medicine, Oregon Health & Science University, Life, Drug discovery, Drug development, Stanford University, 2021 Essex County Council election, R&D, SOS1, Pfizer, Medical college, Hoffmann-La Roche, Oncology, Vanderbilt University, Head, Science, Leadership, Genentech, Indiana University, PRMT5, Health, Research, Therapy, MTA, Management, Pharmaceutical industry, Mirati

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer. In his role, Dr. Sandler will provide leadership and direction over clinical development and operations, regulatory affairs, drug safety and asset development strategy and report to David Meek, chief executive officer. As part of the transition, Dr. James Christensen, executive vice president and chief scientific officer, will also report to Mr. Meek.

Key Points: 
  • As part of the transition, Dr. James Christensen, executive vice president and chief scientific officer, will also report to Mr. Meek.
  • "His extensive experience in drug development, including clinical development experience with adagrasib, will augment our executive leadership at this pivotal time for Mirati.
  • Most recently, Dr. Sandler was president and global head of oncology for Zai Lab where he led global oncology development for the company.
  • He joins Mirati with over 30 years of oncology and drug development experience across industry and academia.

Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors

Retrieved on: 
Monday, November 7, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Annual report, Central nervous system, Science, Therapy, PRMT5, Cancer, MTA, TAM, Safety, Judgement, NSCLC, U.S. Securities and Exchange Commission, COVID-19, Patient, Large-cell lung carcinoma, Marketing, Colorectal cancer, PD-L1, Pancreatic cancer, PD-1, Clinical trial, Life, NASDAQ, Lung cancer, Development, Hematology, Security (finance), SOS1, Solution, Pharmaceutical industry, Medical imaging, Facebook, Research, Mirati, Incyte

We are pleased to collaborate with Mirati to conduct the first clinical trial of INCB99280 plus adagrasib, two orally-bioavailable molecules, in patients with KRASG12C-mutated solid tumors.

Key Points: 
  • We are pleased to collaborate with Mirati to conduct the first clinical trial of INCB99280 plus adagrasib, two orally-bioavailable molecules, in patients with KRASG12C-mutated solid tumors.
  • We are pleased to enter into this agreement with Incyte, supplying adagrasib for evaluation in combination with INCB99280, said Charles Baum, M.D., Ph.D., President, Founder and Head of Research and Development, Mirati Therapeutics, Inc.
  • Under the terms of the agreement, Incyte will initiate and sponsor the Phase 1/1b study of INCB99280 and adagrasib in patients with KRASG12C-mutated solid tumors.
  • Adagrasib is being evaluated in several clinical trials in combination with other anti-cancer therapies in patients with advanced solid tumors.

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, International, Verastem Oncology, Executive, FDA, Pancreatic Cancer Action Network, KRAS, Geron Corporation, Large-cell lung carcinoma, Table, Research, U.S. Securities and Exchange Commission, Mirati, Partnership, SEC, Program, Company, GAAP, Food, MEK, Intellectual property, CEO, Mission statement, Security (finance), Patient, Cancer, INN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Government, USAN, Part, Review, Breakthrough therapy, RAS, Pancreatic cancer, Strategic management, CRAF, RAF, United States Adopted Name, Investment, International nonproprietary name, RAMP, Patent, Safety, NSCLC, FAK, ARAF, Everolimus, Amgen, Oncology, BRAF, Pharmaceutical industry, Medical imaging, Video game, Bank

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.
  • Verastem Oncology ended the three months ended September 30, 2022 (2022 Quarter) with cash, cash equivalents and investments of $104.0 million.
  • Research and development expenses for the 2022 Quarter were $11.3 million, compared to $9.3 million for the 2021 Quarter.
  • Selling, general and administrative expenses for the 2022 Quarter were $6.4 million, compared to $5.5 million for the 2021 Quarter.

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, November 2, 2022
Life, PRMT5, SEC, Cancer, TAM, U.S. Securities and Exchange Commission, Employment, Lung cancer, SOS1, MTA, Judgement, NASDAQ, RSU, Therapy, Patient, SAN, Science, Pharmaceutical industry, Mirati, Facebook

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $67.49 per share, which is equal to the closing price of Mirati's common stock on November 1, 2022, (the "Grant Date").
  • Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Thursday, October 27, 2022
Time, NSCLC, Review, NASDAQ, TSC1, Mirati, Private Securities Litigation Reform Act, Cancer, EORTC, MTOR, KRAS, Forward-looking statement, AMG510, FDA, Perivascular epithelioid cell tumour, Patient, LinkedIn, Adult, Company, Partnership, AADI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Everolimus, Food, TSC2, Mutation, Twitter, Safety, Pharmaceutical industry, Aadi

LOS ANGELES, Oct. 27, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today presented preclinical combination data of KRAS inhibitors and nab-sirolimus at the 34th EORTC-NCI-AACR Symposium. Nab-sirolimus is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Key Points: 
  • The mTOR pathway is often activated in patients with the KRAS mutation and contributes to adaptive resistance to KRAS inhibitors.
  • This study investigated the preclinical antitumor activity of mTOR inhibitors nab-sirolimus or everolimus in combination with sotorasib or adagrasib in KRASG12C-mutated cancer xenografts.
  • "These preclinical results demonstrate that nab-sirolimus has the potential to significantly improve the antitumor activity of adagrasib or sotorasib, two of the most promising KRAS inhibitors today.
  • In contrast, everolimus in combination with the KRAS inhibitors was not as effective.